V8 Peptides — Engineered Performance
Research Library
What Is TB-500? Decoding the Name, Sequence and Mass
TB-500Chemistry

What Is TB-500? Decoding the Name, Sequence and Mass

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is TB-500? TB-500 is a laboratory name for a synthetic peptide based on thymosin beta-4 (Tβ4), a 43-residue, N-terminally acetylated, roughly 4.9 kDa protein that is the main G-actin-sequestering molecule in eukaryotic cells. The name is applied to different molecular forms, so the sequence and mass on the certificate of analysis matter more than the label. On the V8 product page, TB-500 is the 17–23 fragment of Tβ4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ), formula C38H68N10O14, about 889 Da. That sequence is the central actin-binding domain of Tβ4 plus one extra residue. It is supplied for laboratory research use only; not for human consumption.

Anyone who has searched for TB-500 will have found sources that use the name for full-length thymosin beta-4, for a short fragment, or interchangeably. Those are not the same molecule: one is about five times heavier than the other and carries different regions of the parent protein. This article is an identification guide. It explains what thymosin beta-4 is, which part of it the fragment represents, what that part is known to do in published assays, and how to confirm which form is in a vial. The broader background is in the TB-500 research overview, and the parent-versus-fragment comparison is expanded in TB-500 versus thymosin beta-4.

The parent protein: thymosin beta-4

Thymosin beta-4 was first isolated from thymosin fraction 5, prepared from calf thymus, and was initially assumed to be a thymus-specific hormone. Mannherz and Hannappel's review of the beta-thymosins notes that members of the family are N-terminally acetylated peptides of about 5 kDa and 40–44 residues, that they occur in high concentration in the cytoplasm of many eukaryotic cells, and that they bind preferentially to monomeric G-actin and stabilize it in its monomeric form. That makes them the main intracellular actin-sequestering factor, removing monomers from the assembly and disassembly cycles of the cytoskeleton. Hannappel's review of posttranslational modifications adds a chemical detail relevant for identification: during biosynthesis of Tβ4 the initiator methionine is removed and the N-terminus is acetylated.

The quantitative biochemistry comes from Weber and colleagues, who measured the interaction between Tβ4 and muscle and platelet actin. Their abstract reports that Tβ4 forms a 1:1 complex with monomeric actin under physiological salt conditions, that its dissociation constant is not affected by calcium, and that it binds only actin monomers, not filament ends or the sides of filaments. The Tβ4–actin complex does not elongate filaments at either end. For platelet actin they cited a Kd of 0.4–0.7 µM and, using measured concentrations of 280 µM monomeric actin and 560 µM Tβ4, calculated that much of the sequestered actin could be bound to Tβ4 in resting platelets, provided most filaments are barbed-end capped. These are biochemical numbers from purified systems; they are useful here because they define what "actin sequestration" means in practice.

The fragment: where Ac-LKKTETQ comes from

Sosne and colleagues reviewed what is known about the biological activities of Tβ4 as defined by active sites in short peptide sequences. Their abstract describes several: an amino-terminal site of four residues (Ac-SDKP) associated with blocking inflammation and reducing fibrosis, a 15-residue N-terminal region that includes Ac-SDKP and is associated with cell survival and blocking apoptosis, and a short sequence containing LKKTETQ, "the central actin-binding domain (aa 17-23) plus 1 additional amino acid (Q)," that promotes angiogenesis, wound healing and cell migration in the cell and animal systems the review covered. That is the origin of the peptide on the V8 product page: it corresponds to the central actin-binding region of Tβ4 with the acetylated N-terminus carried on the leucine.

Two points deserve emphasis. First, the review attributes particular activities to particular regions; it does not claim that the fragment reproduces all properties of the full protein, and the other active sites (the N-terminal region, the antimicrobial activity and others) lie outside residues 17–23. Second, the fragment's mass is far smaller than that of the parent. Those two facts together explain why naming discipline matters in a methods section: results obtained with full-length Tβ4 cannot be assumed to apply to the fragment, and vice versa. The same caution, from a different angle, appears in TB-500: actin-binding motif and cell migration assays.

PropertyThymosin beta-4 (parent)TB-500 as listed on the V8 page
Length43 residues7 residues (positions 17–23)
Approximate massAbout 4.9–5 kDaAbout 889 Da
N-terminusAcetylated (Ac-SDKP…)Acetylated on leucine (Ac-LKKTETQ)
Actin bindingBinds G-actin 1:1; sequesters monomersContains the central actin-binding stretch
Other active regionsN-terminal Ac-SDKP and 15-residue siteNot included
Typical useCell biology and tissue models of the full proteinFragment-level actin and migration studies

What published assays reported about the parent

Much of the activity literature behind the name concerns the full protein. Malinda and colleagues used several in vitro and in vivo migration assays and reported that Tβ4 acted as a chemoattractant for endothelial cells, stimulating migration of human umbilical vein endothelial cells in Boyden chambers four- to sixfold over medium alone. Of the primary cell types they tested, only human coronary artery cells also responded, which led the authors to describe the activity as endothelial cell-specific. Tβ4 accelerated migration into a scratch-wounded HUVEC monolayer, increased matrix metalloproteinase production, and stimulated cell migration into subcutaneously implanted Matrigel in vivo. The authors called this the first direct evidence of chemoattractive activity and of promotion of angiogenesis through endothelial migration.

These are the assay formats, scratch closure and transwell migration, that the TB-500 product page lists among its research applications along with actin-binding and cytoskeletal research, endothelial tube formation and tissue-response studies. Whether the fragment reproduces the migration response of the whole protein in any given format is a question for each laboratory's own controls; the Sosne review describes the 17–23-plus-Q sequence as active in these categories, but a bench experiment should include the full protein or a scrambled-sequence control where the comparison matters.

How to tell which form you have

Because the name alone does not specify the molecule, identification rests on analytical data. The table below lists what each kind of check can and cannot settle.

CheckWhat it showsWhat it cannot show
Sequence or identity statement on the certificateWhich residues the supplier states are presentWhether the statement was confirmed on the lot in hand, unless backed by data
Molecular formula and massAbout 889 Da for Ac-LKKTETQ versus about 4.9 kDa for full-length Tβ4, a roughly fivefold gapIsomers or sequence scrambles with identical composition
HPLC purityProportion of the main chromatographic peakIdentity; two different peptides can both show a clean peak
Lot number and test dateTraceability of the document to the vialThe condition of the vial after opening

The product page lists the sequence as Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, the formula as C38H68N10O14, a 10 mg vial of lyophilized powder, ≥98% purity by HPLC, and storage at 2–8 °C with −20 °C for long-term and protection from heat, moisture and light. Compare the lot number with the COA library where a certificate has been published, and read how to read a COA for the fields. The reasoning for pairing chromatography with a mass-based identity method is laid out in HPLC versus mass spectrometry.

Bench arithmetic without per-product tables

Two formulas are enough for any stock. Stock concentration (mg/mL) equals vial mass (mg) divided by diluent volume (mL). Molar concentration equals concentration in g/L divided by molar mass in g/mol. The molar form is what makes the parent-versus-fragment distinction concrete: a mass-matched solution of a 889 Da fragment contains many times more molecules than the same mass of a 4.9 kDa protein, so a study that compares the two should say whether concentrations were matched by mass or by moles. The reconstitution calculator performs the volume arithmetic, and how to reconstitute TB-500 covers the physical handling.

Common sources of confusion

Several recurring mix-ups are worth naming. A paper on "thymosin beta-4" may use recombinant or synthetic full-length protein, and its results are not automatically results for a fragment. A paper that says "TB-500" without a sequence is not interpretable until the sequence is found. The Ac-SDKP tetrapeptide, which comes from the N-terminus and is a different region, is sometimes discussed in the same breath, but it is not part of residues 17–23. And "thymosin" in the older literature may refer to thymosin fraction 5 or thymosin alpha-1, both unrelated to this peptide; the latter has its own page at what is thymosin alpha-1.

Where TB-500 sits in a catalog and in a study design

TB-500 is often studied alongside other peptides to separate overlapping pathways, a design discussed in BPC-157 versus TB-500. Anyone building a multi-compound experiment should keep each compound's identity documentation separate and record the form and sequence in the protocol. Other compounds are listed in the research catalog.

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. Thymosin beta-4 is a 43-residue protein of about 4.9 kDa. TB-500 is used as a name for synthetic peptides based on it. On the V8 product page it is the 17–23 fragment, Ac-LKKTETQ, of about 889 Da. Always check the sequence and mass on the certificate.

What does the LKKTET motif do?

It is the central actin-binding region of thymosin beta-4. Sosne and colleagues describe the sequence LKKTETQ, residues 17–23, as active in promoting angiogenesis, wound healing and cell migration in the studies they reviewed.

How does thymosin beta-4 bind actin?

Per Weber and colleagues' measurements, it forms a 1:1 complex with monomeric actin, binds only monomers and not filament ends or sides, and the complex does not elongate filaments.

Why is the mass so different between the two forms?

The parent has 43 residues and the fragment has 7, so the fragment is roughly one-fifth the mass. That large gap makes mass-based identification a straightforward way to tell them apart.

What cell assays is TB-500 used in?

The product page lists actin-binding and cytoskeletal research, cell-migration and angiogenesis models, and tissue-response studies. Scratch and transwell migration, and endothelial tube formation, are the common formats.

What did early migration studies show for the parent protein?

Malinda and colleagues reported that thymosin beta-4 stimulated HUVEC migration four- to sixfold over medium alone in Boyden chambers, accelerated scratch-wound closure and increased matrix metalloproteinase production.

Does HPLC purity tell me which molecule is in the vial?

No. HPLC reports the proportion of the main peak, not what the peak is. Identity needs a sequence statement and a mass-based or equivalent confirmation.

How is the concentration of a stock calculated?

Vial mass in mg divided by diluent volume in mL gives mg/mL. Divide g/L by molar mass in g/mol to get a molar value. The calculator on this site does the arithmetic.

How should lyophilized TB-500 be stored?

The page states refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Is the N-terminal acetyl group important?

It is a defining chemical feature of thymosin beta-4, which is acetylated at the N-terminus after the initiator methionine is removed, and the fragment on the V8 page is likewise written with an acetylated N-terminus.

All material discussed is supplied for laboratory research use only; not for human consumption.

Related reading: TB-500 Research Questions, Answered With Sources, TB-500 Mechanism: When Thymosin β4 Knockouts Disagree, TB-500 Muscle and Ligament Animal Studies: Endpoints.

References

  1. Mannherz HG, Hannappel E. The beta-thymosins: intracellular and extracellular activities of a versatile actin binding protein family. Cell Motil Cytoskeleton. 2009;66(10):839-851. doi:10.1002/cm.20371
  2. Hannappel E. Thymosin beta4 and its posttranslational modifications. Ann N Y Acad Sci. 2010;1194:27-35. doi:10.1111/j.1749-6632.2010.05485.x
  3. Weber A, et al. Interaction of thymosin beta 4 with muscle and platelet actin: implications for actin sequestration in resting platelets. Biochemistry. 1992;31(27):6179-6185. doi:10.1021/bi00142a002
  4. Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. doi:10.1096/fj.09-142307
  5. Malinda KM, Goldstein AL, Kleinman HK. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J. 1997;11(6):474-481. doi:10.1096/fasebj.11.6.9194528
  6. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.